Evidence map›Paper›PMID 30111627›Full record

ArticlemSphere2018

Aminoglycoside Heteroresistance in Acinetobacter baumannii AB5075.

Sarah E Anderson, Edgar X Sherman, David S Weiss, Philip N Rather

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Heteroresistance to amikacin inMicrobiology spectrum · 2026
    Article
  5. Article
  6. Article
  7. An Investigation of Colistin Heteroresistance inBioMed research international · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Theoretical considerations and empirical predictions of the pharmaco- and population dynamics of heteroresistance.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sarah E AndersonDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Edgar X ShermanDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
David S WeissDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA.
Philip N RatherDepartment of Microbiology and Immunology, Emory University, Atlanta, Georgia, USA prather@emory.edu.
Emory University · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Antimicrobial Resistance and Therapeutic Discovery Training ProgramT32AI106699 · NIAID · EMORY UNIVERSITY · PI Graeme L Conn, Joanna B Goldberg · 2014 to 2026
$2.7M
ArmR: a novel drug target and mediator of antibiotic resistanceR33AI098800 · NIAID · EMORY UNIVERSITY · PI WEISS, DAVID S · 2014 to 2016
$1.6M
ArmR: a novel drug target and mediator of antibiotic resistanceR21AI098800 · NIAID · EMORY UNIVERSITY · PI WEISS, DAVID S · 2012 to 2013
$473k
BLRD VA I01 BX001725BLRD VA I01 BX002788BLRD VA IK6 BX004470NIAID NIH HHS R21 AI098800NIAID NIH HHS R33 AI098800NIAID NIH HHS T32 AI106699NIH HHS P51 OD011132
6 · The paper itself

Abstract

Heteroresistance is a phenomenon where a subpopulation of cells exhibits higher levels of antibiotic resistance than the general population. Analysis of tobramycin resistance in

Indexed as

Drug Resistance, BacterialAcinetobacter baumanniiAmikacinAminoglycosidesAnti-Bacterial AgentsDisk Diffusion Antimicrobial TestsGentamicinsHumansIntegronsNucleotidyltransferasesPlasmidsTobramycinAmikacinAminoglycosidesAnti-Bacterial AgentsGentamicinsNucleotidyltransferasesTobramycinAcinetobacter baumanniiaminoglycoside-modifying enzymesgene amplificationheteroresistance

Identifiers

PMID30111627
PMCPMC6094062
OpenAlexW2887214263

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.